| Name | Title | Contact Details |
|---|
WellAir provides an ecosystem for healthy indoor air by delivering innovative and powerful air disinfection technology and surface disinfection devices. Our best in class solutions are used worldwide in healthcare, education, commercial and industrial ...
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.
Eurogentec North America is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Our vision is a world where genomic information is fully accessible, understandable and integrated into health and well being. We are on a mission to help patients and healthcare providers use genetic services to improve health, lower the cost of care, and prevent disease.
NeoChord is a venture backed medical device company that has developed a proprietary device which allows mitral valve repair to be performed on a beating heart through a 2- to 3-inch incision between the ribs in patients with severe mitral valve regurgitation (MR). In contrast, most mitral valve repair procedures are performed through a 3 to 10 inch chest incision (sternotomy) that involves cutting through the sternum, opening the rib cage, stopping the heart and placing the patient on cardio-pulmonary bypass (CPB).